Key Takeaways
- Phase II is primarily for market learning; Phase III converts learning into operational decisions.
- First-launch companies need longer lead time because capabilities are often built from zero.
- Roadmaps should sequence leadership, access, organization and governance—not only promotional tactics.
- Use illustrative timing; actual sequencing depends on therapy, indication and market.
Emerging biotechnology companies benefit from a shared commercialization roadmap that connects clinical progress to commercial readiness.
This is not a universal calendar. It is a way to organize decisions so capabilities are not discovered eighteen months before launch when they require three years to build. For a visual stage view, see the 36-month launch roadmap.
Phase II: Learn the Market
Focus on diagnosed versus theoretical opportunity, patient journey, referral networks, Centers of Excellence, competitive evolution and early evidence gaps. Commercial infrastructure can remain lean while commercial thinking becomes rigorous.
Phase III: Convert Understanding Into Decisions
Leadership should increasingly define commercialization model, organizational design, hiring sequence, Market Access capabilities, Medical Affairs expansion, patient services, distribution and launch governance.
This is also when a formal launch readiness assessment often creates disproportionate value.
Pre-Approval: Execution Intensifies
As approval approaches, the organization must demonstrate that plans translate into owners, milestones, systems and cross-functional accountability. First-launch companies should treat this as organizational transformation—see first commercial launch advisory.
Use a Shared Readiness Language
The Commercial Readiness Framework—Market Reality, Patient Journey, Evidence, Access, Organization, Leadership and Execution—helps keep roadmap conversations coherent across the CEO, board and functional leaders.
Illustrative planning framework; actual timing depends on the company, therapy, indication and market.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
